Business
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management will host a conference call tomorrow, May 15 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.
About this update from Volitionrx Limited
[{"type":"text","content":"Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time","length":126,"tagName":"p","attribs":{}},{"type":"text","content":"HENDERSON, Nev., May 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management will host a conference call tomorrow, May 15 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.","length":435,"tagName":"p"},{"type":"text","content":"Cameron Reynolds, President and Group Chief Executive Officer, said:","length":68,"tagName":"p"},{"type":"text","content":""We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end.","length":131,"tagName":"p"},{"type":"text","content":""We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform.","length":403,"tagName":"p"},{"type":"text","content":""We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives.","length":386,"tagName":"p"},{"type":"text","content":""We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic[1], we demonstrated Nu.Q® NETs' potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,[2] which affects about 1% of the world's population....